Park Avenue Securities LLC Has $450,000 Stock Holdings in Bruker Co. (NASDAQ:BRKR)

Park Avenue Securities LLC grew its position in Bruker Co. (NASDAQ:BRKR) by 8.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 4,786 shares of the medical research company’s stock after buying an additional 362 shares during the period. Park Avenue Securities LLC’s holdings in Bruker were worth $450,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in BRKR. Lindbrook Capital LLC grew its holdings in Bruker by 68.2% during the 4th quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock worth $26,000 after acquiring an additional 146 shares during the period. Rise Advisors LLC bought a new stake in Bruker in the first quarter valued at about $27,000. Neo Ivy Capital Management acquired a new position in Bruker in the fourth quarter valued at about $30,000. VisionPoint Advisory Group LLC boosted its holdings in Bruker by 145.0% during the third quarter. VisionPoint Advisory Group LLC now owns 512 shares of the medical research company’s stock worth $32,000 after buying an additional 303 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new position in shares of Bruker during the 4th quarter worth about $33,000. Institutional investors own 79.52% of the company’s stock.

Analysts Set New Price Targets

BRKR has been the topic of several recent analyst reports. The Goldman Sachs Group lifted their price objective on shares of Bruker from $66.00 to $74.00 and gave the stock a “sell” rating in a research note on Wednesday, April 10th. Jefferies Financial Group assumed coverage on shares of Bruker in a report on Monday, June 3rd. They issued a “buy” rating and a $85.00 price target for the company. Bank of America dropped their price objective on Bruker from $95.00 to $90.00 and set a “buy” rating on the stock in a research note on Monday, May 20th. Stifel Nicolaus decreased their target price on Bruker from $81.00 to $77.00 and set a “hold” rating for the company in a research note on Monday, May 20th. Finally, StockNews.com lowered Bruker from a “buy” rating to a “hold” rating in a research report on Tuesday, May 21st. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $85.00.

Bruker Stock Down 0.6 %

NASDAQ:BRKR opened at $63.81 on Friday. The company has a market cap of $9.27 billion, a PE ratio of 23.20, a PEG ratio of 2.17 and a beta of 1.25. The stock has a 50-day simple moving average of $71.53 and a 200 day simple moving average of $77.42. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.91 and a current ratio of 1.81. Bruker Co. has a 52-week low of $53.79 and a 52-week high of $94.86.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The company had revenue of $721.70 million for the quarter, compared to the consensus estimate of $729.88 million. During the same period last year, the company earned $0.64 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. On average, sell-side analysts expect that Bruker Co. will post 2.66 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 17th. Investors of record on Monday, June 3rd were paid a $0.05 dividend. The ex-dividend date was Monday, June 3rd. This represents a $0.20 annualized dividend and a dividend yield of 0.31%. Bruker’s dividend payout ratio is presently 7.27%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.